Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)‘s stock had its “equal weight” rating reissued by equities researchers at Barclays PLC in a report released on Wednesday. They presently have a $16.00 price objective on the biotechnology company’s stock, down from their previous price objective of $17.00. Barclays PLC’s price target would indicate a potential upside of 15.94% from the company’s current price.

MNTA has been the subject of a number of other reports. Goldman Sachs Group, Inc. (The) started coverage on shares of Momenta Pharmaceuticals in a research note on Thursday, September 28th. They set a “neutral” rating and a $18.00 target price for the company. BidaskClub upgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Zacks Investment Research lowered shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. Maxim Group set a $6.00 target price on shares of Momenta Pharmaceuticals and gave the company a “sell” rating in a research note on Thursday, August 3rd. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $15.00 target price (down from $22.00) on shares of Momenta Pharmaceuticals in a research note on Wednesday. Two analysts have rated the stock with a sell rating, seven have given a hold rating and one has assigned a buy rating to the stock. Momenta Pharmaceuticals has an average rating of “Hold” and an average target price of $15.44.

Shares of Momenta Pharmaceuticals (NASDAQ MNTA) traded down 8.61% during trading on Wednesday, reaching $13.80. The company’s stock had a trading volume of 3,180,657 shares. The company’s market capitalization is $1.02 billion. Momenta Pharmaceuticals has a one year low of $10.75 and a one year high of $19.90. The firm’s 50-day moving average price is $16.76 and its 200-day moving average price is $15.80.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.50). Momenta Pharmaceuticals had a negative net margin of 39.35% and a negative return on equity of 12.28%. The company had revenue of $23.57 million during the quarter, compared to analyst estimates of $24.64 million. During the same period in the previous year, the business earned ($0.31) EPS. The firm’s revenue for the quarter was down 10.8% on a year-over-year basis. On average, equities analysts anticipate that Momenta Pharmaceuticals will post ($1.53) earnings per share for the current year.

WARNING: “Momenta Pharmaceuticals, Inc. (MNTA) Receives Equal Weight Rating from Barclays PLC” was originally published by Marea Informative and is the property of of Marea Informative. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at http://www.mareainformativa.com/momenta-pharmaceuticals-inc-mnta-price-target-cut-to-16-00-by-analysts-at-barclays-plc/117910/.

In other news, President Craig A. Wheeler sold 35,667 shares of the company’s stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $19.03, for a total value of $678,743.01. Following the completion of the sale, the president now directly owns 286,121 shares in the company, valued at approximately $5,444,882.63. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, President Craig A. Wheeler sold 4,116 shares of the company’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $15.07, for a total value of $62,028.12. Following the completion of the sale, the president now owns 269,231 shares of the company’s stock, valued at $4,057,311.17. The disclosure for this sale can be found here. Insiders sold a total of 79,663 shares of company stock valued at $1,414,498 over the last 90 days. 4.40% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of the company. FMR LLC increased its stake in shares of Momenta Pharmaceuticals by 3.3% in the 2nd quarter. FMR LLC now owns 11,125,193 shares of the biotechnology company’s stock worth $188,015,000 after purchasing an additional 351,743 shares in the last quarter. BlackRock Inc. increased its stake in shares of Momenta Pharmaceuticals by 7.1% in the 2nd quarter. BlackRock Inc. now owns 9,400,485 shares of the biotechnology company’s stock worth $158,868,000 after purchasing an additional 626,415 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Momenta Pharmaceuticals by 4.9% in the 2nd quarter. Vanguard Group Inc. now owns 6,243,767 shares of the biotechnology company’s stock worth $105,519,000 after purchasing an additional 290,090 shares in the last quarter. State Street Corp increased its stake in shares of Momenta Pharmaceuticals by 8.1% in the 2nd quarter. State Street Corp now owns 2,653,427 shares of the biotechnology company’s stock worth $44,842,000 after purchasing an additional 197,978 shares in the last quarter. Finally, Palo Alto Investors LLC increased its stake in shares of Momenta Pharmaceuticals by 1.6% in the 2nd quarter. Palo Alto Investors LLC now owns 1,787,576 shares of the biotechnology company’s stock worth $30,210,000 after purchasing an additional 28,200 shares in the last quarter. Hedge funds and other institutional investors own 93.86% of the company’s stock.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Analyst Recommendations for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Stock Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.